MDT

96.16

+0.02%↑

A

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

MDT

96.16

+0.02%↑

A

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

MDT

96.16

+0.02%↑

A

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

MDT

96.16

+0.02%↑

A

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

MDT

96.16

+0.02%↑

A

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

Search

Penumbra Inc

Open

BrancheGesundheitswesen

306.09 -1.6

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

301.8

Max

310.81

Schlüsselkennzahlen

By Trading Economics

Einkommen

581K

46M

Verkäufe

15M

355M

KGV

Branchendurchschnitt

75.153

88.032

Gewinnspanne

12.927

Angestellte

4,500

EBITDA

4M

55M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+8.46% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

3.5B

12B

Vorheriger Eröffnungskurs

307.69

Vorheriger Schlusskurs

306.09

Nachrichtenstimmung

By Acuity

50%

50%

141 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Penumbra Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Dez. 2025, 22:20 UTC

Wichtige Markttreiber

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31. Dez. 2025, 17:31 UTC

Wichtige Markttreiber

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31. Dez. 2025, 16:30 UTC

Wichtige Markttreiber

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31. Dez. 2025, 15:19 UTC

Wichtige Markttreiber

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31. Dez. 2025, 15:17 UTC

Wichtige Markttreiber

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31. Dez. 2025, 14:37 UTC

Wichtige Markttreiber

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

1. Jan. 2026, 23:35 UTC

Market Talk

Gold Rises Amid Geopolitical Risks -- Market Talk

1. Jan. 2026, 21:29 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13

1. Jan. 2026, 21:29 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Sold Stake in JV to Tata Steel

1. Jan. 2026, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31

1. Jan. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. Jan. 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. Dez. 2025, 21:13 UTC

Akquisitionen, Fusionen, Übernahmen

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31. Dez. 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31. Dez. 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31. Dez. 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31. Dez. 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31. Dez. 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31. Dez. 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31. Dez. 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31. Dez. 2025, 17:16 UTC

Wichtige Markttreiber

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31. Dez. 2025, 17:00 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31. Dez. 2025, 15:57 UTC

Akquisitionen, Fusionen, Übernahmen

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31. Dez. 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31. Dez. 2025, 15:02 UTC

Wichtige Markttreiber

Nike Shares Rise After CEO Hill Buys $1M of Shares

31. Dez. 2025, 14:40 UTC

Akquisitionen, Fusionen, Übernahmen

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31. Dez. 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31. Dez. 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

Peer-Vergleich

Kursveränderung

Penumbra Inc Prognose

Kursziel

By TipRanks

8.46% Vorteil

12-Monats-Prognose

Durchschnitt 337.21 USD  8.46%

Hoch 388 USD

Tief 266 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Penumbra Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

15 ratings

14

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

288.28 / 292.9394Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

141 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat